A strong performance in its native business and the EU, alongside depreciation of the yen, allowed Japanese generics firm Towa Pharmaceutical Co. Ltd. to deliver a standout first quarter, after experiencing something of a rough ride during the previous financial year.
Net sales in the domestic segment were up 19.2% year on year, to ¥43bn ($295m), due to sales growth of...








